148 related articles for article (PubMed ID: 19578225)
21. Seroconversion after measles vaccination at nine and fifteen months of age.
Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
[TBL] [Abstract][Full Text] [Related]
22. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
23. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
Giorgi-Rossi P; Merito M; Borgia P
Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
[TBL] [Abstract][Full Text] [Related]
26. Impact of mass measles campaigns among children less than 5 years old in Uganda.
Nanyunja M; Lewis RF; Makumbi I; Seruyange R; Kabwongera E; Mugyenyi P; Talisuna A
J Infect Dis; 2003 May; 187 Suppl 1():S63-8. PubMed ID: 12721893
[TBL] [Abstract][Full Text] [Related]
27. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
28. Migration as a risk factor for measles after a mass vaccination campaign, Burkina Faso, 2002.
Yaméogo KR; Perry RT; Yaméogo A; Kambiré C; Kondé MK; Nshimirimana D; Kezaala R; Hersh BS; Cairns KL; Strebel P
Int J Epidemiol; 2005 Jun; 34(3):556-64. PubMed ID: 15659463
[TBL] [Abstract][Full Text] [Related]
29. Trend of measles morbidity in Thailand.
Ariyasriwatana C
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S707-18. PubMed ID: 14700171
[TBL] [Abstract][Full Text] [Related]
30. [Measles in Poland in 2002].
Czarkowski MP; Kondej B
Przegl Epidemiol; 2004; 58(1):21-7. PubMed ID: 15218638
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin.
Kaucley L; Levy P
Cost Eff Resour Alloc; 2015; 13():14. PubMed ID: 26300696
[TBL] [Abstract][Full Text] [Related]
32. Supplementary statement on measles elimination in canada.
Can Commun Dis Rep; 1996 Jan; 22(2):9-15. PubMed ID: 8924894
[TBL] [Abstract][Full Text] [Related]
33. Mathematical models of cervical cancer prevention in Latin America and the Caribbean.
Goldie SJ; Diaz M; Constenla D; Alvis N; Andrus JK; Kim SY
Vaccine; 2008 Aug; 26 Suppl 11():L59-72. PubMed ID: 18945403
[TBL] [Abstract][Full Text] [Related]
34. Experience in global measles control, 1990-2001.
Henao-Restrepo AM; Strebel P; John Hoekstra E; Birmingham M; Bilous J
J Infect Dis; 2003 May; 187 Suppl 1():S15-21. PubMed ID: 12721887
[TBL] [Abstract][Full Text] [Related]
35. Measles vaccination effectiveness among children under 5 years of age in Kampala, Uganda.
Mupere E; Karamagi C; Zirembuzi G; Grabowsky M; de Swart RL; Nanyunja M; Mayanja H
Vaccine; 2006 May; 24(19):4111-5. PubMed ID: 16554111
[TBL] [Abstract][Full Text] [Related]
36. [Cost-effectiveness analysis on two different measles immunization strategies].
Wu H; Wang K; Zhang X; Jin S; Feng Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Apr; 21(2):121-3. PubMed ID: 11860771
[TBL] [Abstract][Full Text] [Related]
37. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of two dose measles vaccination in a community setting.
Phadke MA; Bhargava I; Dhaigude P; Bagade A; Biniwale MA; Kurlekar SU
Indian Pediatr; 1998 Aug; 35(8):723-5. PubMed ID: 10216565
[TBL] [Abstract][Full Text] [Related]
39. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
